What are the facts and artifacts of the pathogenesis and etiology of Alzheimer disease?

Journal of Chemical Neuroanatomy

Volumn 16, Issue 1, 1998, Pages 35-41

  Smith, Mark A ^a   Perry, George ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; ALZHEIMER DISEASE; ARTICLE; CELL VIABILITY; HUMAN; NERVE DEGENERATION; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL;

AGED; AGING; ALUMINUM; ALZHEIMER DISEASE; BRAIN; HUMANS;

EID: 0032465384     PISSN: 08910618     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-0618(98)00061-1     Document Type: Article

References (90)

1. Allsop D., Haga S.-I., Haga C., Ikeda S.-I., Mann D.M.A., Ishii T. Early senile plaques in Down's syndrome brains show a close relationship with cell bodies of neurons. Neuropathol. Appl. Neurobiol. 15:1989;531-542.
2. Alzheimer, A., 1907. In: Rottenberg, D.A., Hochberg, F.H. (Eds.), Allg. Z. Psychiatrie Psychisch-Gerichtliche Medizin 64, 146-148. Translated in Neurological Classics in Modern Translation, 1977. Hafner Press, New York, pp. 41-43.
3. Alzheimer, A., 1907. In: Rottenberg, D.A., Hochberg, F.H. (Eds.), Allg. Z. Psychiatrie Psychisch-Gerichtliche Medizin 64, 146-148. Translated in Neurological Classics in Modern Translation, 1977. Hafner Press, New York, pp. 41-43.
4. Baudier, J., Cole, R.D., 1987. The phosphorylation of the microtubule-associated tau. In: Perry, G. (Ed.), Advances in Behavioral Biology 34: Alterations in the Neuronal Cytoskeleton in Alzheimer Disease. Plenum Press, New York, pp. 25-32.
5. Bennett D.A., Cochran E.J., Saper C.B., Leverenz J.B., Gilley D.W., Wilson R.S. Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer's disease. Neurobiol. Aging. 14:1993;589-596.
6. Benzi G., Moretti A. Are reactive oxygen species involved in Alzheimer's disease? Neurobiol. Aging. 16:1995;661-674.
7. Bizzi A., Crane R.C., Autilio-Gambetti L., Gambetti P. Aluminum effect on slow axonal transport: a novel impairment of neurofilament transport. J. Neurosci. 4:1984;722-731.
8. Blessed G., Tomlinson B.E., Roth M. The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Brit. J. Psychiat. 114:1968;797-811.
9. Bondareff W., Harrington C.R., Wischik C.M., Hauser D.L., Roth M. Absence of abnormal hyperphosphorylation of tau in intracellular tangles in Alzheimer's disease. J. Neuropathol. Exp. Neurol. 54:1995;657-663.
10. Bosman G.J., Bartholomeus I.G., de Grip W.J. Alzheimer's disease and cellular aging: membrane-related events as clues to primary mechanisms. Gerontology. 37:1991;95-112.
11. Candy J.M., Oakley A.E., Klinowski J. et al. Aluminosilicates and senile plaque formation in Alzheimer's disease. Lancet. 1:1986;354-357.
12. Canning D.R., McKeon R.J., DeWitt D.A., Perry G., Wujek J.R., Frederickson R.C.A., Silver J. β-amyloid of Alzheimer's disease induces reactive gliosis that inhibits axonal outgrowth. Exp. Neurol. 124:1993;289-298.
13. Choo-Smith L.P., Garzon-Rodriguez W., Glabe C.G., Surewicz W.K. Acceleration of amyloid fibril formation by specific binding of Aβ-(1-40) peptide to ganglioside-containing membrane vesicles. J. Biol. Chem. 272:1997;22987-22990.
14. Corder E.H., Saunders A.M., Strittmatter W.J. et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 261:1993;921-923.
15. Crapper D.R., Krishnan S.S., Dalton A.J. Brain aluminum distribution in Alzheimer's disease and experimental neurofibrillary degeneration. Science. 180:1973;511-513.
16. Crapper D.R., Krishnan S.S., Quittkat S. Aluminium, neurofibrillary degeneration and Alzheimer's disease. Brain. 99:1976;67-80.
17. Cras P., Kawai M., Lowery D., Gonzalez-DeWhitt P., Greenberg B., Perry G. Senile plaque neurites in Alzheimer disease accumulate amyloid precursor protein. Proc. Natl. Acad. Sci. USA. 88:1991;7552-7556.
18. DeWitt D.A., Perry G., Cohen M., Doller C., Silver J. Astrocytes regulate microglial phagocytosis of senile plaque cores of Alzheimer's disease. Exp. Neurol. 149:1998;329-340.
19. Frautschy S.A., Cole G.M., Baird A. Phagocytosis and deposition of vascular beta-amyloid in rat brains injected with Alzheimer beta-amyloid. Am. J. Pathol. 140:1992;1389-1399.
20. Goedert M., Jakes R., Crowther R.A. et al. The abnormal phosphorylation of tau protein at Ser-202 in Alzheimer disease recapitulates phosphorylation during development. Proc. Natl. Acad. Sci. USA. 90:1993;5066-5070.
21. Good P.F., Perl D.P., Bierer L.M., Schmeidler J. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. Ann. Neurol. 31:1992;286-292.
22. Grant W.B. Dietary links to Alzheimer's disease. Alz. Dis. Rev. 2:1997;42-55.
23. Hardy J.A., Higgins G.A. Alzheimer's disease: the amyloid cascade hypothesis. Science. 256:1992;184-185.
24. Hensley K., Hall N., Subramaniam R. et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65:1995;2146-2156.
25. Hofman A., Ott A., Breteler M.M. et al. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam study. Lancet. 349:1997;151-154.
26. Hsiao K., Chapman P., Nilsen S. et al. Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science. 274:1996;99-102.
27. Iversen L.L., Mortishire-Smith R.J., Pollack S.J., Shearman M.S. The toxicity in vitro of β-amyloid protein. Biochem. J. 331:1995;1-16.
28. Kanayama G., Takeda M., Niigawa H. et al. The effects of repetitive mild brain injury on cytoskeletal protein and behavior. Methods Findings Exp. Clin. Pharmacol. 18:1996;105-115.
29. Kawai M., Kalaria R.N., Harik S.I., Perry G. The relationship of amyloid plaques to cerebral capillaries in Alzheimer's disease. Am. J. Pathol. 137:1990;1435-1446.
30. Khachaturian Z.S. Diagnosis of Alzheimer's disease. Arch. Neurol. 42:1985;1097-1105.
31. Klatzo I., Wisniewski H.M., Streicher E. Experimental production of neurofibrillary degeneration. J. Neuropathol. Exp. Neurol. 24:1965;187-199.
32. Landsberg J.P., McDonald B., Watt F. Absence of aluminium in neuritic plaque cores in Alzheimer's disease. Nature. 360:1992;65-68.
33. Mann D.M.A., Marcyniuk B., Yates P.O., Neary D., Snowden J.S. The progression of the pathological changes of Alzheimer's disease in frontal and temporal neocortex examined both at biopsy and at autopsy. Neuropathol. Appl. Neurobiol. 14:1988;177-195.
34. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Rad. Biol. Med. 23:1997;134-147.
35. Martyn C.N., Barker D.J., Osmond C., Harris E.C., Edwardson J.A., Lacey R.F. Geographical relation between Alzheimer's disease and aluminum in drinking water. Lancet. 1:1989;59-62.
36. Masliah E., Terry R.D., DeTeresa R.M., Hansen L.A. Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci. Lett. 103:1989;234-239.
37. Masliah E., Terry R.D., Mallory M., Alford M., Hansen L.A. Diffuse plaques do not accentuate synapse loss in Alzheimer's disease. Am. J. Pathol. 137:1990;1293-1297.
38. McDermott J.R., Smith A.I., Iqbal K., Wisniewski H.M. Brain aluminum in aging and Alzheimer disease. Neurology. 29:1979;809-814.
39. McLachlan D.R., Bergeron C., Smith J.E., Boomer D., Rifat S.L. Risk for neuropathologically confirmed Alzheimer's disease and residual aluminum in municipal drinking water employing weighted residential histories. Neurology. 46:1996;401-405.
40. McShea A., Harris P.L.R., Webster K.R., Wahl A.F., Smith M.A. Abnormal expression of the cell cycle regulators p16 and CDK4 in Alzheimer's disease. Am. J. Pathol. 150:1997;1933-1939.
41. Mirra S.S., Heyman A., McKeel D. et al. The consortium to establish a registry for Alzheimer's disease (CERAD): Part II, standardization of the neuropathologic assessment of Alzheimers disease. Neurology. 41:1991;479-486.
42. Morris J.C., Storandt M., McKeel D.W.J., Rubin E.H., Price J.L., Grant E.A., Berg L. Cerebral amyloid deposition and diffuse plaques in 'normal' aging: evidence for presymptomatic and very mild Alzheimer's disease. Neurology. 46:1996;707-719.
43. Murphy G.M.J., Eng L.F., Ellis W.G., Perry G., Meissner L.C., Tinklenberg J.R. Antigenic profile of plaques and neurofibrillary tangles in the amygdala in Down's syndrome: a comparison with Alzheimer's disease. Brain Res. 537:1990;102-108.
44. Nitsch R.M., Blusztajn J.K., Pittas A.G., Slack B.E., Growdon J.H., Wurtman R.J. Evidence for a membrane defect in Alzheimer disease brain. Proc. Natl. Acad. Sci. USA. 89:1992;1671-1675.
45. Odetti P., Angelini G., Dapino D. et al. Early glycoxidation damage in brains from Down's syndrome. Biochem. Biophys. Res. Comm. 243:1998;849-851.
46. Perl D.P., Brody A.R. Alzheimer's disease: X-ray spectrometric evidence of aluminum accumulation in neurofibrillary tangle-bearing neurons. Science. 208:1980;297-299.
47. Perry, G., Lipphardt, S., Mulvihill, P., Kancherla, M., Mijares, M., Gambetti, P., Sharma, S., Maggiora, L., Cornette, J., Lobl, T., Greenberg, B., 1988. Amyloid precursor protein in senile plaques of Alzheimer disease. Lancet ii, 746.
48. Perry G., Cras P., Kawai M., Mulvihill P., Tabaton M. Transformation of neurofibrillary tangles in the extracellular space. Bull. Clin. Neurosci. 56:1991;107-119.
49. Perry G., Smith M.A. Senile plaques and neurofibrillary tangles: what role do they play in Alzheimer's disease? Clin. Neurosci. 1:1993;199-203.
50. Perry, G., Smith, M.A., 1998. The case of vascular abnormalities in Alzheimer disease. Invest. Drugs Res. Alert (in press).
51. Praprotnik D., Smith M.A., Richey P.L., Vinters H.V., Perry G. Plasma membrane fragility in dystrophic neurites in senile plaques of Alzheimer's disease: an index of oxidative stress. Acta Neuropathol. 91:1996;1-5.
52. Praprotnik D., Smith M.A., Richey P.L., Vinters H.V., Perry G. Filament heterogeneity within the dystrophic neurites of senile plaques suggests blockage of fast axonal transport in Alzheimer's disease. Acta Neuropathol. 91:1996;226-235.
53. Richey P.L., Siedlak S.L., Smith M.A., Perry G. Apolipoprotein E interaction with the neurofibrillary tangles and senile plaques in Alzheimer disease: implications for disease pathogenesis. Biochem. Biophys. Res. Commun. 208:1995;657-663.
54. Rifenburg R.P., Perry G. Dystrophic neurites define diffuse as well as core-containing senile plaques in Alzheimer's disease. Neurodegeneration. 4:1995;235-237.
55. Roberts G.W., Gentleman S.M., Lynch A., Graham D.I. BetaA4 amyloid protein deposition in brain after head trauma. Lancet. 338:1991;1422-1423.
56. Roses A.D. Apolipoprotein E affects the rate of Alzheimer's disease expression: β-amyloid burden is a secondary consequence dependent on ApoE genotype and duration of disease. J. Neuropathol. Exp. Neurol. 53:1994;429-437.
57. Roth M., Tomlinson B.E., Blessed G. Correlation between scores for dementia and counts of'senile plaques in cerebral grey matter of elderly subjects. Nature. 209:1966;109-110.
58. Roth M., Tomlinson B.E., Blessed G. The relationship between quantitative measures of dementia and of degenerative changes in the cerebral grey matter of elderly subjects. Proc. Royal Soc. Med. 60:1967;254-260.
59. Roth G.S., Joseph J.A., Mason R.P. Membrane alterations as causes of impaired signal transduction in Alzheimer's disease and aging. Trends Neurosci. 18:1995;203-206.
60. Saitoh T., Masliah E., Jin L.W., Cole G.M., Wieloch T., Shapiro I.P. Protein kinases and phosphorylation in neurologic disorders and cell death. Lab. Invest. 64:1991;596-616.
61. Sayre L.M., Zagorski M.G., Surewicz W.K., Krafft G.A., Perry G. Mechanisms of neurotoxicity associated with amyloid β deposition and the role of free radicals in the pathogenesis of Alzheimer's disease: a critical appraisal. Chem. Res. Toxicol. 10:1997;518-526.
62. Selkoe D.J. Alzheimer's disease: genotypes phenotypes and treatments. Science. 275:1997;630-631.
63. Scheff S.W., DeKosky S.T., Price D.A. Quantitative assessment of cortical synaptic density in Alzheimer's disease. Neurobiol. Aging. 11:1990;29-37.
64. Smith C.D., Carney J.M., Starke-Reed P.E., Oliver C.N., Stadtman E.R., Floyd R.A., Marksberry W.R. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc. Natl. Acad. Sci. USA. 88:1991;10540-10543.
65. Smith, M.A., 1998. Alzheimer disease. In: Bradley, R.J., Harris, R.A. (Eds.), International Review of Neurobiology, 42. Academic Press, San Diego, pp. 1-54.
66. Smith M. A., Perry G. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J. Neuropathol. Exp. Neurol. 56:1997;217.
67. Smith M.A., Siedlak S.L., Richey P.L. et al. Tau protein directly interacts with the amyloid β-protein precursor: Implications for Alzheimer's disease. Nature Med. 1:1995;365-369.
68. Smith M.A., Sayre L.M., Monnier V.M., Perry G. Radical AGEing in Alzheimer's disease. Trends Neurosci. 18:1995;172-176.
69. Smith M.A., Sayre L.M., Perry G. Diabetes mellitus and Alzheimer's disease: glycation as a biochemical link. Diabetologia. 39:1996;247.
70. Smith M.A., Siedlak S.L., Richey P.L., Nagaraj R.H., Elhammer A., Perry G. Quantitative solubilization and analysis of insoluble paired helical filaments from Alzheimer disease. Brain Res. 717:1996;99-108.
71. Smith M.A., Perry G., Richey P.L., Sayre L.M., Anderson V.E., Beal M.F., Kowall N. Oxidative damage in Alzheimer's. Nature. 382:1996;120-121.
72. Smith M.A., Petot G.J., Perry G. Diet and oxidative stress: a novel synthesis of epidemiological data on Alzheimer's disease. Alz. Dis. Rev. 2:1997;58-60.
73. Smith M.A., Harris P.L.R., Sayre L.M., Beckman J.S., Perry G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci. 17:1997;2653-2657.
74. Smith M.A., Harris P.L.R., Sayre L.M., Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA. 94:1997;9866-9868.
75. Smith M.A., Hirai K., Hsiao K. et al. Amyloid-β deposition in Alzheimer transgenic mice initiates oxidative stress. J. Neurochem. 70:1998;2212-2215.
76. Smith M.A., Wehr K., Harris P.L.R., Siedlak S.L., Connor J.R., Perry G. Abnormal localization of iron regulatory protein (IRP) in Alzheimer disease. Brain Res. 788:1998;232-236.
77. Snow A.D., Mar H., Nochlin D., Sekiguchi R.T., Kimata K., Koike Y., Wight T.N. Early accumulation of heparan sulfate in neurons and in the β-amyloid protein-containing lesions of Alzheimer's disease and Down's syndrome. Am. J. Pathol. 137:1990;1253-1270.
78. Snowdon D.A., Greiner L.H., Mortimer J.A., Riley K.P., Greiner P.A., Markesbery W.R. Brain infarction and the clinical expression of Alzheimer disease: the Nun study. J. Am Med Assoc. 277:1997;813-817.
79. Sternberger N.H., Sternberger L.A., Ulrich J. Aberrant neurofilament phosphorylation in Alzheimer disease. Proc. Natl. Acad. Sci. USA. 82:1985;4274-4276.
80. Strittmatter W.J., Weisgraber K.H., Huang D.Y. et al. Binding of human apolipoprotein E to synthetic amyloid β peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc. Natl. Acad. Sci. USA. 90:1993;8098-8102.
81. Suzuki K., Terry R.D. Fine structural localization of acid phosphatase in senile plaques in Alzheimer's presenile dementia. Acta Neuropathol. 8:1967;276-284.
82. Teller J.K., Russo C., DeBusk L.M. et al. Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nature Med. 2:1996;93-95.
83. Terry R.D. The pathogenesis of Alzheimer disease: an alternative to the amyloid hypothesis. J. Neuropath. Exp. Neurol. 55:1996;1023-1025.
84. Terry R.D., Peña C. Experimental production of neurofibrillary degeneration. J. Neuropathol. Exp. Neurol. 24:1965;200-210.
85. Tomlinson B.E., Blessed G., Roth M. Observations on the brains of demented old people. J. Neurol. Sci. 11:1970;205-242.
86. Trojanowski J.Q., Schmidt M.L., Shin R.-W., Bramblett G.T., Goedert M., Lee V.M.-Y. PHFτ (A68): from pathological marker to potential mediator of neuronal dysfunction and degeneration in Alzheimer's disease. Clin. Neurosci. 1:1993;184-191.
87. Troncoso J.C., Sternberger N.H., Sternberger L.A., Hoffman P.N., Price D.L. Immunocytochemical studies of neurofilament antigens in the neurofibrillary pathology induced by aluminum. Brain Res. 364:1986;295-300.
88. WAF1/CIP1 in neurons following focal cerebral ischemia. Neuroscience. 84:1998;1097-1112.
89. Whitson J.S., Mims M.P., Strittmatter W.J., Yamaki T., Morrisett J.D., Appel S.H. Attenuation of the neurotoxic effect of Aβ amyloid peptide by apolipoprotein E. Biochem. Biophys. Res. Commun. 199:1994;163-170.
90. Wilcock G.K., Esiri M.M. Plaques, tangles and dementia: a quantitative study. J. Neurol. Sci. 56:1982;343-356.